XLO - Xilio Therapeutics, Inc.
Price:
--
--
|
CONSENSUS:
Buy
DETAILS
|
PRICE TARGET:
$98.00
DETAILS
HIGH:
$98.00
LOW:
$98.00
MEDIAN:
$98.00
CONSENSUS:
$98.00
UPSIDE:
1087.88%
Institutional Holders (13F)
| GURU | SHARES | VALUE | WEIGHT % | SHARES CHG | ACTION |
|---|---|---|---|---|---|
| Wood | 0 | $0 | -- | -4,000,000 | SOLD |
Insider Trading
| DATE | INSIDER | TITLE | TYPE | SHARES | PRICE | VALUE |
|---|---|---|---|---|---|---|
| 2026-04-15 | Blanchard Cheryl R | director | A-Award | 10,000 | $8.40 | $84K |
| 2026-04-15 | Blanchard Cheryl R | ? | -- | -- | -- | |
| 2026-03-26 | Shannon James Samuel | director | BUY | 5,000 | $8.79 | $44K |
| 2026-02-13 | GILEAD SCIENCES, INC. | 10 percent owner | BUY | 3,739,000 | $0.00 | $373 |
| 2026-01-02 | Frankenfield Christopher James | officer: Chief Financial Officer | SELL | 7,030 | $0.64 | $5K |
| 2026-01-01 | Brennan Kevin M. | officer: SVP, FINANCE AND ACCOUNTING | M-Exempt | 5,000 | -- | -- |
| 2026-01-02 | Brennan Kevin M. | officer: SVP, FINANCE AND ACCOUNTING | SELL | 1,826 | $0.64 | $1K |
| 2025-12-31 | Frankenfield Christopher James | officer: Chief Financial Officer | A-Award | 668,789 | $0.84 | $562K |
| 2025-12-31 | Russo Rene | director, officer: PRESIDENT AND CEO | A-Award | 1,500,258 | $0.84 | $1.3M |
| 2026-01-01 | Frankenfield Christopher James | officer: Chief Financial Officer | M-Exempt | 19,375 | -- | -- |
| 2026-01-01 | Russo Rene | director, officer: PRESIDENT AND CEO | M-Exempt | 44,250 | -- | -- |
| 2025-12-31 | Luptakova Katarina | officer: CHIEF MEDICAL OFFICER | A-Award | 451,885 | $0.84 | $380K |
| 2026-01-01 | Luptakova Katarina | officer: CHIEF MEDICAL OFFICER | M-Exempt | 16,625 | -- | -- |
| 2025-12-31 | Brennan Kevin M. | officer: SVP, FINANCE AND ACCOUNTING | A-Award | 95,221 | $0.84 | $80K |
| 2025-11-26 | GILEAD SCIENCES, INC. | 10 percent owner | X-InTheMoney | 13,335,000 | $0.75 | $10.0M |
| 2025-11-21 | Frankenfield Christopher James | officer: Chief Financial Officer | A-Award | 155,090 | $1.50 | $233K |
| 2025-11-21 | Frankenfield Christopher James | officer: Chief Financial Officer | A-Award | 150,000 | $1.50 | $225K |
| 2025-11-21 | Luptakova Katarina | officer: CHIEF MEDICAL OFFICER | D-Return | 106,000 | $2.79 | $296K |
| 2025-11-21 | Luptakova Katarina | officer: CHIEF MEDICAL OFFICER | D-Return | 44,210 | $9.69 | $428K |
| 2025-11-21 | Russo Rene | director, officer: PRESIDENT AND CEO | A-Award | 2,075,000 | $0.84 | $1.7M |
| 2025-11-21 | Russo Rene | director, officer: PRESIDENT AND CEO | D-Return | 135,134 | $11.69 | $1.6M |
| 2025-11-21 | Luptakova Katarina | officer: CHIEF MEDICAL OFFICER | A-Award | 25,000 | $1.50 | $38K |
| 2025-11-21 | Frankenfield Christopher James | officer: Chief Financial Officer | A-Award | 925,000 | $0.84 | $778K |
| 2025-11-21 | Frankenfield Christopher James | officer: Chief Financial Officer | A-Award | 300,000 | $1.50 | $450K |
| 2025-11-21 | Luptakova Katarina | officer: CHIEF MEDICAL OFFICER | A-Award | 15,000 | $1.50 | $22K |